Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study-Reference-Cited by-同舟云学术

Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study

Published:2009-09 Issue:13 Volume:45 Page:2298-2303
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Scagliotti Giorgio V.,Park Keunchil,Patil Shekar,Rolski Janusz,Goksel Tuncay,Martins Renato,Gans Steven J.M.,Visseren-Grul Carla,Peterson Patrick

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference24 articles.

1. Management of metastatic non-small cell lung cancer in 2006: innovations and unique clinical scenarios;Martins,2006

2. NCCN clinical practice guidelines in oncology: non-small cell lung cancer. National Comprehensive Cancer Network. ; 2009 [accessed 31.03.09].

3. ESMO Guidelines Working Group. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up;D’Addario;Ann Oncol,2008

4. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial;Manegold;Ann Oncol,2000

5. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group;Shepherd;Cancer,2001

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model;Frontiers in Public Health;2023-02-24

2. A Structural Analysis of Proteinaceous Nanotube Cavities and Their Applications in Nanotechnology;Nanomaterials;2022-11-20

3. Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis;Frontiers in Pharmacology;2022-09-29

4. Conventional Chemotherapy Nephrotoxicity;Advances in Chronic Kidney Disease;2021-09

5. The efficacy and safety of combination therapy with immune checkpoint inhibitors in non-small cell lung cancer: A meta-analysis;International Immunopharmacology;2021-07